© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
December 14, 2020
Urologist Adam J. Gadzinski, MD, MS, shares how telemedicine can help improve access to urologic care.
Angela B. Smith, MD, MS, discusses how her institution has adjusted how it conducts clinical trials in the COVID-19 era.
December 11, 2020
The analyses are from a pivotal phase 3 trial of nadofaragene firadenovec which previously met its primary end point of complete response.
“As urologists, we all need to start speaking in risk stratification criteria,” says Katie Murray, DO.
December 10, 2020
Angela B. Smith, MD, MS, describes her institution’s early clinical experience with mitomycin-containing reverse thermal gel (Jelmyto).
December 09, 2020
Murray also discusses the low-grade upper tract urothelial cancer treatment mitomycin-containing reverse thermal gel (Jelmyto).
Dr. Declan G. Murphy discusses results from the phase 3 proPSMA study of Ga 68 PSMA-11 in patients with high-risk prostate cancer.
December 04, 2020
Arjun V. Balar, MD, discusses combination treatment with pembrolizumab (Keytruda) and axitinib (Inlyta) in the first-line setting for metastatic RCC.
“[Low-grade upper tract urothelial carcinoma] is fairly uncommon, yet it’s common enough that every urologist comes across it,” says Surena F. Matin, MD.